TeraRecon to Sell EnvoyAI Platform
|
By HospiMedica International staff writers Posted on 12 Dec 2017 |

Image: TeraRecon has entered into a distribution partnership with EnvoyAI to sell and market the EnvoyAI platform (Photo courtesy of TeraRecon).
TeraRecon (Foster City, CA, USA), a provider of advanced visualization solutions, has entered into a distribution partnership with EnvoyAI (Cambridge, MA, USA) to sell and market the EnvoyAI platform. The platform includes a content-rich artificial intelligence (AI) marketplace, called the EnvoyAI Exchange, as well as a suite of market-ready AI-enablement technologies aimed at fostering broader access and clinical use of medical imaging algorithms within busy radiology practices.
TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.
As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.
“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”
TeraRecon provides advanced visualization, image viewing and post-processing solutions that leverage AI to improving radiology workflow through personalized automation features for increased efficiency. EnvoyAI provides a developer platform, integrations, and an API interface for algorithm developers, technology partners, and end-users. It facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. The platform allows users anywhere to access cloud-based algorithms without requiring access to the algorithm code or training data to protect PHI and developer intellectual property. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.
As a distributor of EnvoyAI, TeraRecon will offer instant access to the platform containing more than 35 algorithms and initially focus on driving sales on two FDA-cleared algorithms from Imbio and icometrix, as well as one of its own cleared algorithms. Imbio offers lung density reporting for COPD analysis with chest CT scans. The Imbio CT Lung Density Analysis software provides reproducible CT values for pulmonary tissue, which is essential for providing quantitative support for diagnosis and follow up examinations. icometrix offers icobrain, an FDA-cleared brain MRI tool that is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures from a set of MR images. The software is intended to automate the current manual process of identifying, labeling and quantifying the volumes of segmentable brain structures identified on MR images. TeraRecon offers iNtuition Time Density Analysis for CT, which supports stroke triage workflow by producing colorized parametric maps of the brain from time-resolved, thin-slice CT scans of the head with contrast, including CBF, CBV, MTT, TTP, TOT, RT map types.
“The automated outputs from Imbio and icometrix elevate the standard of care without creating additional work for radiologists,” said Jeff Sorenson, President and CEO of TeraRecon. “The combined workflows achieved by TeraRecon and EnvoyAI deliver these results in a fast, flexible, and extensible way allowing our customers to easily introduce AI into their medical imaging enterprise.”
Channels
Artificial Intelligence
view channelCritical Care
view channel
Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems
Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more
AI Stethoscope Spots Heart Valve Disease Earlier Than GPs
Valvular heart disease affects more than half of people over 65, yet it often goes undiagnosed until symptoms become severe. In advanced stages, untreated cases can carry a mortality risk of up to 80%... Read more
Bioadhesive Patch Eliminates Cancer Cells That Remain After Brain Tumor Surgery
Glioblastoma is the most common and aggressive form of brain tumor, characterized by rapid growth, high invasiveness, and an extremely poor prognosis. Even with surgery followed by radiotherapy and chemotherapy,... Read moreSurgical Techniques
view channel
AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries
Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more
Neural Device Regrows Surrounding Skull After Brain Implantation
Placing electronic implants on the brain typically requires removing a portion of the skull, creating challenges for long-term access and safe closure. Current methods often involve temporarily replacing... Read morePatient Care
view channel
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
VR Training Tool Combats Contamination of Portable Medical Equipment
Healthcare-associated infections (HAIs) impact one in every 31 patients, cause nearly 100,000 deaths each year, and cost USD 28.4 billion in direct medical expenses. Notably, up to 75% of these infections... Read more
Portable Biosensor Platform to Reduce Hospital-Acquired Infections
Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read moreFirst-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds
Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read moreHealth IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel
Medtronic to Acquire Coronary Artery Medtech Company CathWorks
Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Medtronic and Mindray Expand Strategic Partnership to Ambulatory Surgery Centers in the U.S.
Mindray North America and Medtronic have expanded their strategic partnership to bring integrated patient monitoring solutions to ambulatory surgery centers across the United States. The collaboration... Read more
FDA Clearance Expands Robotic Options for Minimally Invasive Heart Surgery
Cardiovascular disease remains the world’s leading cause of death, with nearly 18 million fatalities each year, and more than two million patients undergo open-heart surgery annually, most involving sternotomy.... Read more







